Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $16.2 million versus the consensus estimate of $14.02 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.